Top

International Journal of Clinical Oncology

Published in:

01-04-2014 | Original Article

Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma

Authors: Toshihiko Matsuo, Yuka Ogino, Kouichi Ichimura, Takehiro Tanaka, Mitsumasa Kaji

Published in: International Journal of Clinical Oncology | Issue 2/2014

Abstract

Background

The purpose of this study was to redefine the role of whole-body 2-[¹⁸F]fluoro-2-deoxy-d-glucose (FDG) positron emission tomography fused with computed tomography (PET/CT) in the clinical diagnosis of choroidal malignant melanoma.

Methods

The study design was a retrospective case series involving 7 consecutive patients with choroidal malignant melanoma who underwent enucleation to reach the final pathological diagnosis. FDG-PET/CT was performed together with magnetic resonance imaging and ophthalmological examinations before the surgery. The area, thickness, longest diameter, and circumference of the tumor mass were measured on pathological sections, and were correlated with maximum standardized uptake values (SUVmax) of the tumors on FDG-PET/CT.

Results

Abnormally high uptake of FDG was noted in the affected eyes of 5 patients, but not in the eyes of 2 patients. The 5 patients with high uptake showed nodular tumors extruding into the vitreous cavity while the 2 patients with absence of uptake showed diffusely infiltrating tumors in the wide area of the choroid with or without a small mushroom-like protrusion. One patient with diffuse infiltration showed concurrent liver metastases with high uptake on PET/CT while another patient with a nodular tumor developed liver metastases a year later. The tumors with higher SUVmax had a tendency to have a wider area and greater thickness on pathological sections (ρ = 0.775, P = 0.0557, Spearman rank correlation test).

Conclusions

FDG-PET/CT showed correlation of the uptake with tumor sizes but was limited in detecting diffusely infiltrating tumors in the choroid without nodular formation.

Straatsma BR, Diener-West M, Caldwell R et al (2003) Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol 136:47–54PubMedCrossRef

Freudenberg LS, Schueler AO, Beyer T et al (2004) Whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 49:537–540PubMedCrossRef

Finger PT, Kurli M, Wesley P et al (2004) Whole body PET/CT imaging for detection of metastatic choroidal melanoma. Br J Ophthalmol 88:1095–1097PubMedCentralPubMedCrossRef

Kurli M, Reddy S, Tena LB et al (2005) Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol 140:193–199PubMedCrossRef

Reddy S, Kurli M, Tena LB et al (2005) PET/CT imaging: detection of choroidal melanoma. Br J Ophthalmol 89:1265–1269PubMedCentralPubMedCrossRef

Finger PT, Kurli M, Reddy S et al (2005) Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 89:1270–1274PubMedCentralPubMedCrossRef

Finger PT, Chin K, Iacob CE (2006) 18-fluorine-labelled 2-deoxy-2-fluoro-d-glucose positron emission tomography/computed tomography standardized uptake values: a non-invasive biomarker for the risk of metastasis from choroidal melanoma. Br J Ophthalmol 90:1263–1266PubMedCentralPubMedCrossRef

Bawa M, Sidhu G, Galt JR et al (2006) Choroidal melanoma with hematogenous spread to the liver: F-18 FDG PET/CT findings. Clin Nucl Med 31:347–348PubMedCrossRef

Francken AB, Fulham MJ, Millward MJ et al (2006) Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur J Surg Oncol 32:780–784PubMedCrossRef

10.

Faia LJ, Pulido JS, Donaldson MJ et al (2008) The relationship between combined positron emission tomography/computed tomography and clinical and light microscopic findings in choroidal melanoma. Retina 28:763–769PubMedCrossRef

11.

Klingenstein A, Haug AR, Nentwich MM et al (2010) Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma. Melanoma Res 20:511–516PubMedCrossRef

12.

Servois V, Mariani P, Malhaire C et al (2010) Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 36:189–194CrossRef

13.

Goto H, Usui M, Ishii I (2001) Efficacy of ¹²³ N-isopropyl-p-[¹²³I]-iodoamphetamine single photon emission computed tomography for the diagnosis of uveal malignant melanoma. Am J Ophthalmol 132:937–939PubMedCrossRef

14.

Goto H (2004) Clinical efficacy of ¹²³I-IMP SPECT for the diagnosis of malignant uveal melanoma. Int J Clin Oncol 9:74–78PubMedCrossRef

15.

Sou R, Oku N, Ohguro N et al (2004) The clinical role of N-isopropyl-p-[¹²³I]-iodoamphetamine single photon emission computed tomography in the follow-up of choroidal melanoma after radiotherapy. Jpn J Ophthalmol 48:54–58PubMedCrossRef

16.

Kato K, Kubota T, Ikeda M et al (2006) Low efficacy of ¹⁸F-FDG PET for detection of uveal malignant melanoma compared with ¹²³I-IMP SPECT. J Nucl Med 47:404–409PubMed

17.

Abe K, Sasaki M, Koga H et al (2007) Clinical role of ¹²³I-IMP SPECT for the differential diagnosis of ocular malignant melanoma: a time-course analysis. Nucl Med Commun 28:567–573PubMedCrossRef

18.

Yoshimura M, Kanesaka N, Saito K et al (2011) Diagnosis of uveal malignant melanoma by a new semiquantitative assessment of N-isopropyl-p-[¹²³I]-iodoamphetamine. Jpn J Ophthalmol 55:148–154PubMedCrossRef

19.

Patel K, Sullivan K, Berd D et al (2005) Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15:297–304PubMedCrossRef

20.

Vogl T, Eichler K, Zangos S et al (2007) Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 133:177–184PubMedCrossRef

21.

Sharma KV, Gould JE, Harbour JW et al (2008) Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol 190:99–104PubMedCrossRef

22.

Dayani PN, Gould JE, Brown DB et al (2009) Hepatic metastasis from uveal melanoma. Angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 127:628–632PubMedCrossRef

23.

Ishihara K, Saida T, Otsuka F et al (2008) Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 13:33–44PubMedCrossRef

24.

Tsutsumida A, Furukawa H, Yamamoto Y et al (2005) Treatment strategy for cutaneous malignant melanoma. Int J Clin Oncol 10:311–317PubMedCrossRef

25.

Finger PT (1997) Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232PubMedCrossRef

26.

Zehetmayer M, Kitz K, Menapace R et al (2000) Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 55:135–144PubMedCrossRef

27.

Mueller AJ, Talies S, Schaller UC et al (2000) Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology 107:1381–1388PubMedCrossRef

28.

Collaborative Ocular Melanoma Study Group (1998) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II: initial mortality findings. COMS Report No. 10. Am J Ophthalmol 125:779–796CrossRef

29.

Collaborative Ocular Melanoma Study Group (2004) The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. ten-year mortality findings and prognostic factors. COMS Report Number 24. Am J Ophthalmol 138:936–951CrossRef

30.

Finger PT, Chin KJ (2011) [¹⁸F] fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy. Int J Radiat Oncol Biol Phys 79:137–142PubMedCrossRef

31.

Collaborative Ocular Melanoma Study Group (1998) Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study COMS Report No. 6. Am J Ophthalmol 125:745–766CrossRef

Title: Clinicopathological correlation for the role of fluorodeoxyglucose positron emission tomography computed tomography in detection of choroidal malignant melanoma
Authors: Toshihiko Matsuo
Yuka Ogino
Kouichi Ichimura
Takehiro Tanaka
Mitsumasa Kaji
Publication date: 01-04-2014
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-013-0538-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials

Is biomarker research advancing in the era of personalized medicine for head and neck cancer?

Clinicopathologic characteristics and survival of male breast cancer

Curcumin targets the AKT–mTOR pathway for uterine leiomyosarcoma tumor growth suppression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer